MedTrace Logo

Revascularization in Heart Failure Trial - REHEAT 2

NCT00388245 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2006-10-16

No results posted yet for this study

Summary

REHEAT 2 study is designed as a prospective, randomised trial comparing two strategies of myocardial revascularisation (PCI vs CABG) in patients with ischemic cardiomyopathy and low left ventricular ejection fraction.Patients will undergo in random way PCI or CABG procedure. The aim the study is to assess the improvement of left ventricle systolic function and comparing recent (30 days) and late (12 months) results of surgical (CABG) and percutaneous (PCI) revascularization.

Conditions

  • Left Ventricular Ejection Fraction
  • Myocardial Revascularization
  • Ischemic Heart Disease

Interventions

PROCEDURE

Percutaneous Coronary Intervention

PROCEDURE

Coronary Artery Bypass Grafting

Sponsors & Collaborators

  • Ministry of Science and Higher Education, Poland

    lead OTHER_GOV

Principal Investigators

  • Pawel E Buszman, Prof · 3-rd Division of Cardiology, University School of Silesia, Poland

  • Michal Tendera, Prof · 3-rd Division of Cardiology, University School of Silesia, Poland

  • Andrzej Bochenek, Prof · 1-st Division of Cardiosurgery, University School of Silesia, Poland

  • Robert J Gil, Prof · Invasive Cardiology Department, Central Clinic Hospital, Warsaw, Poland

  • Piotr Ponikowski, Prof · Heart Disease Department, Military Clinic Hospital, Wroclaw, Poland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2008-12-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00388245 on ClinicalTrials.gov